Novartis teams with advocacy group to bring visibility to atherosclerotic cardiovascular disease

Novartis and cardiovascular disease patient advocacy group, Global Heart Hub, have joined forces to make the dangers atherosclerotic cardiovascular disease (ASCVD) more visible through the “Invisible Nation” initiative.

The program is called “The Invisible Nation,” because despite heart disease being billed as “the world’s No. 1 killer” and ASCVD accounting for 85% of cardiovascular-related deaths, ASCVD itself remains largely unknown. Buried under the umbrella of “cardiovascular disease,” ASCVD is itself another umbrella term describing a mix of cardiovascular diseases caused by plaque buildup that blocks arteries and can lead to heart attacks and stroke.